A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Trial Profile

A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs GSK 2816126 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jul 2017 Status changed from recruiting to discontinued, as the maximal dose and schedule attained with GSK2816126 has shown insufficient evidence of clinical activity, and does not justify further clinical investigation.
    • 17 May 2017 Planned primary completion date changed from 1 Dec 2017 to 21 Jun 2018.
    • 06 Dec 2016 Results of part 1 of this trial (n=30) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top